Abstract
Labradimil (Cereport®; also formerly referred to as RMP-7) is a 9-amino-acid peptide designed for selectivity for the bradykinin B2 receptor and a longer plasma half-life than bradykinin. It has been developed to increase the permeability of the blood-brain barrier (BBB) and is the first compound with selective bradykinin B2 receptor agonist properties to progress from concept design through to tests of efficacy in patients.
In vitro studies demonstrate that labradimil has a longer half-life than bradykinin and selectively binds to bradykinin B2 receptors, initiating typical bradykinin-like second messenger systems, including increases in intracellular calcium and phosphatidylinositol turnover. Initial proof of principle studies using electron microscopy demonstrated that intravenous labradimil increases the permeability of the BBB by disengaging the tight junctions of the endothelial cells that comprise the BBB. Autoradiographic studies in rat models further demonstrated that labradimil increases the permeability of the BBB in gliomas. Intravenous or intra-arterial labradimil increases the uptake of many different radiolabelled tracers and chemotherapeutic agents into the tumour in a dose-related fashion. These effects are selective for the tumour and for the brain surrounding the tumour, and are particularly robust in tumour areas that are normally relatively impermeable. The increased chemotherapeutic concentrations are maintained for at least 90 minutes, well beyond the transient effects on the BBB.
The increase in permeability with labradimil occurs rapidly but is transient, in that restoration of the BBB occurs very rapidly (2 to 5 minutes) following cessation of infusion. Even with continuous infusion of labradimil, spontaneous restoration of the barrier begins to occur within 10 to 20 minutes. Collectively, these data demonstrate that the B2 receptor system that modulates permeability of the BBB is highly sensitive and autoregulated and that careful attention to the timing of labradimil and the chemotherapeutic agent is important to achieve maximal effects.
Survival studies in rodent models of both gliomas and metastatic tumours in the brain demonstrate that the enhanced uptake observed with the combination of labradimil and water-soluble chemotherapeutics enhances survival to a greater extent than achieved with chemotherapy alone. Finally, preliminary clinical trials in patients with gliomas provide confirmatory evidence that labradimil permeabilises the blood-brain tumour barrier and might, therefore, be used to increase delivery of agents such as carboplatin to tumours without the toxicity typically associated with dose escalation.
Similar content being viewed by others
References
Davson H, Segal M. Physiology of the CSF and blood-brain barriers. Boca Raton (FL): CRC Press, 1996
Pardridge W. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Deliv Rev 1995; 15: 5–36
Rapoport S. Blood-brain barrier in physiology and medicine. New York: Raven Press, 1976
Bartus RT. The blood-brain barrier as a target for pharmacological modulation. Curr Opin Drug Disc Dev 1999; 2(2): 152–67
Betz A. An overview of the multiple functions of the blood-brain barrier. In: Frankenheim J, Brown R, editors. Bioavailability of drugs to the brain and the blood-brain barrier. Washington, DC: US Government Printing Office, 1992: 54–72
Zlokovic B, McComb J, Perlmutter L, et al. Neuroactive peptides and amino acid at the blood-brain barrier: possible implications for drug abuse. In: Frankenheim J, Brown R, editors. Bioavailability of drugs to the brain and the blood-brain barrier. Washington, DC: US Government Printing Office, 1992: 26–42
Black K. Biochemical opening of the blood-brain barrier. Adv Drug Deliv Rev 1995; 15: 37–52
Raymond J, Robertson D, Dinsdale H. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Physiol Pharmacol 1986; 13: 214–20
Inamura T, Black KL. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 1994; 14: 862–70
Nomura T, Inamura T, Black K. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res 1994; 658: 62–6
Bhoola K, Figueroa C, Worthy K. Bioregulation of kinins: kallikreins, kininogens and kinases. Pharm Rev 1992; 44: 1–80
Erdös E. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990; 15 Suppl. 6: S20–4
Kumakura S, Kamo I, Tsurufuji S. Role of bradykinin in the vascular permeability response induced by carrageenin in rats. Br J Pharmacol 1988; 93: 739–46
Grous J, Elliott P, Bartus R. Development of RMP-7: a novel bradykinin agoinst that increases delivery of chemotherapeutics to gliomas. In: Salmon S, editor. Adjuvant therapy of cancer. Philadelphia (PA): Lippincott-Raven, 1997: 19–31
Boddy A, Thomas H. RMP-7: potential as an adjuvant to the drug treatment of brain tumours. CNS Drugs 1997; 7(4): 257–63
Regoli D, Rhaleb N, Drapeau G, et al. Kinin receptor subtypes. J Cardiovasc Pharmacol 1990; 15 Suppl 6: S30–8
Hess J, Borkowski J, Young G, et al. Cloning and pharmacological characterization of a human bradykinin (B2) receptor. Biochem Biophys Res Commun 1992; 184: 260–8
Menke J, Borkowski J, Bierlo K, et al. Expression cloning of a human B1 bradykinin receptor. J Biol Chem 1994; 269: 21583–6
Hamayoun P, Harik S. Bradykinin receptors of cerebral microvessels stimulate phosphoinositide turnover. J Cereb Blood Flow Metab 1991; 11: 557–66
Doctrow SR, Abelleira SM, Curry LA, et al. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther 1994; 271: 229–37
Unterberg A, Wahl M, Baethmann A. Effects of bradykinin on permeability and diameter of pial vessels in vivo. J Cereb Blood Flow Metab 1984; 4: 574–85
Wahl M, Young A, Edvinnson L, et al. Effects of bradykinin on pial arteries and arterioles in vitro and in situ. J Cereb Blood Flow Metab 1983; 3: 231–7
Yong T, Gao X, Koizumi S, et al. Role of peptidases in bradykinin-induced increase in vascular permeability in vivo. Circ Res 1992; 70: 952–9
Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32: 1–46
Regoli D, Marceau F, Lavigne J. Induction of B1 receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol 1981; 71: 105–15
Dray A, Perkins M. Bradykinin and inflammatory pain. Trends Neurosci 1993; 16: 99–104
Kozarich J, Musso G, Malfroy-Camine B. Increasing blood-brain barrier permeability with permeabilizer peptides. Cambridge (MA): Alkermes, Inc., 1993
Marceau F, Gendreau M, Barabe J, et al. The degradation of bradykinin (BK) and of des-Arg9-BK in plasma. Can J Physiol Pharmacol 1981; 39: 131–8
Regoli D, Drapeau G, Dion S, et al. New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci 1988; 9: 290–5
Rhaleb N, Telemaque S, Rouissi N, et al. Structure-activity studies of bradykinin and related peptides: B2-receptor antagonists. Hypertension 1991; 17: 107–15
Bartus RT, Elliott P, Hayward N, et al. Permeability of the BBB by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. Immunopharmacology 1996; 33: 270–8
McCarthy D, Potter D, Nicolaides E. An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. J Pharmacol Exp Ther 1965; 148: 117–22
Straub JA, Akiyama A, Parmar P. In vitro plasma metabolism of RMP-7. Pharm Res 1994; 11: 1673–6
Sanovich E, Bartus RT, Friden PM, et al. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 1995; 705: 125–35
Elliott PJ, Hayward NJ, Dean RL, et al. Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res 1996; 56: 3998–4005
Emerich D, Snodgrass P, Pink M, et al. Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7). Brain Res 1998; 801: 259–66
Elliott P, Hayward N, Dean R, et al. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist RMP-7. Immunopharmacology 1996; 33: 205–8
Riley M, Kim N, Watson V, et al. Intraarterial administration of the bradykinin agonist, RMP-7 and carboplatin: a toxicologie evaluation in swine. J Neurooncol 1998; 36: 167–78
Bartus RT, Elliott PJ, Dean RL, et al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 1996; 142: 14–28
Elliott PJ, Hayward NJ, Huff MR, et al. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol 1996; 141: 214–24
Bartus R, Snodgrass P, Dean R, et al. Evidence that Cereport’s ability to increase permeability of rat gliomas in dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies. Exp Neurol 2000; 161: 234–44
Del Maestro R. Angiogenesis. In: Berger M, Wilson C, editors. The gliomas. Philadelphia (PA): WB Saunders, 1999: 87–106
Stewart P, Farrell C, Del Maestro R. The effect of cellular microenvironment on vessels in the brain. Part 1: vessel structure in tumour, peritumour and brain from humans with malignant glioma. Int J Radiat Biol 1991; 60: 125–30
Emerich D, Snodgrass P, Dean R, et al. Enhanced uptake of carboplatin into brain tumors with intravenous Cereport (RMP-7): dramatic differences as a function of dosing parameters. Br J Cancer 1999; 80: 964–70
St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197–202
Bartus R, Snodgrass P, Dean R, et al. Use of Cereport (RMP-7) to increase delivery of carboplatin to gliomas: insight and parameters for intracarotid infusion via a single-lumen cannula. Drug Deliv 1999; 6: 15–21
Barth R, Yang W, Moeschberger M, et al. Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analogue, Cereport (RMP-7). Neurosurgery 1999; 47: 189–98
Hochberg F, Pruit A. Assumptions from the radiotherapy of glioblastoma. Neurology 1980; 30: 907–11
Lesser G, Grossman S. The chemotherapy of high grade astrocytomas. Semin Oncol 1994; 21: 220–35
Walner K, Galichih J, Krol G, et al. Patterns of failure following treatment of glioblastoma and anaplatic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16: 1405–9
Nelson D, McDonald J, Lapham L, et al. Central nervous system tumors. In: Rubin R, McDonald S, Qazi R, editors. Clinical oncology. Philadelphia (PA): WB Saunders, 1992: 617–44
Inamura T, Nomura T, Bartus R, et al. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 1994; 81: 752–8
Nakano S, Matsukado K, Black K. Enhanced cytokines delivery and intercellular adhesion molecule 1 (ICAM-1) expression in glioma by intracarotid infusion of bradykinin analog, RMP-7. Neurol Res 1997; 19: 501–8
Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881–7
Bartus R, Snodgrass P, Marsh J, et al. Intravenous Cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels and enhances survival. J Pharmacol Exp Ther 2000; 293(3): 903–11
Emerich D, Dean R, Marsh J, et al. Intravenous Cereport (RMP-7) enhances delivery of carboplatin and increases survival in rats with metastatic tumors in the brain. Pharm Res 2000 Oct; 17(10): 1212–9
Fike J, Gobbel G, Mesiwala A, et al. Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain. J Neurooncol 1998; 37: 199–215
Snodgrass P, Emerich D, Bartus R. Obligatory tachyphylaxis of bradykinin B2 receptors following increased permeability of the blood brain barrier by intravenous Cereport [abstract]. Society for Neuroscience; 2000 Nov 4–9; New Orleans
Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 1996; 39: 125–34
Black K, Cloughesy T, Huang S, et al. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 1997; 86: 603–9
Cloughesy T, Black K, Gobin Y, et al. Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery 1999; 44: 270–8
Ford JM, Miles KA, Hayball MP, et al. A simplified technique for measurement of blood-brain barrier permeability using CT: preliminary results of the effect of RMP-7. In: Faulkner K, Carey B, Crellin A, et al., editors. Quantitative imaging in oncology. London: British Institute of Radiology, 1996: 1–3
Ford J, Osborn C, Barton T, et al. A Phase I study of intravenous Cereport (RMP-7) with carboplatin patients with progression of malignant glioma. Eur J Cancer 1998; 34(11): 1807–11
Gregor A, Lind M, Newman H, et al. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. J Neurooncol 1999; 44: 137–45
Thomas H, Newell D, Calvert A, et al. Clinical studies with the novel bradykinin analog RMP-7 and carboplatin in patients with glioma [abstract]. Br J Cancer 1996; 73: 15
Siddik Z, Grous J, Chang S, et al. Pharmacokinetics of carboplatin and RMP-7 in patients with recurrent malignant glioma [abstract]. American Society of Clinical Oncology Annual Meeting; 1996 May 18–21; Philadelphia
Yung W, Mechtler L, Gleason M. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991; 9: 860–4
Osborn C, Stenning S, Downing G. Survival following treatment with RMP-7 and carboplatin in malignant glioma who grade III-IV: comparison with matched controls. European Congress of Clinical Oncologists; 1997 Sep; Hamburg, Germany.
Postmus PE, Smit EF, Haaxma-Reiche H, et al., and the European Organization for Research and Treatment of Cancer: Lung Cancer Cooperative Group. Teniposide for brain metastastases of small-cell lung cancer: a phase II study. J Clin Oncol 1995; 13: 660–6
Boogerd W, Sande JVD, Zandwijk NV. Teniposide sometimes effective in brain metastases from non-small cell lung cancer. J Neurooncol 1999; 41: 285–9
Jain R. Critical issues in tumor microcirculation, angiogenesis and metastasis: biological significance and clinical relevance [course notes]. Cambridge (MA): Harvard Medical School, 1996
Emerich D, Snodgrass P, Dean R, et al. Bradykinin modulation of tumor vasculature I: activation of B2 receptors increases delivery of chemotherpaeutic agents into solid peripheral tumors, enhancing their efficacy. J Pharmacol Exp Ther 2001; 296: 623–31
Emerich D, Snodgrass P, Dean R, et al. Bradykinin modulation of tumor vasculature II: activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modify vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J Pharmacol Exp Ther 2001; 296: 632–41
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Emerich, D.F., Dean, R.L., Osborn, C. et al. The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier. Clin Pharmacokinet 40, 105–123 (2001). https://doi.org/10.2165/00003088-200140020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200140020-00003